4 results
Approved WMOPending
To evaluate the efficacy of crovalimab compared to eculizumab
Approved WMOCompleted
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
Approved WMOPending
To evaluate the safety and tolerability of crovalimab compared witheculizumab
Approved WMOCompleted
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.